Objective: The aim of the study was to investigate the potential clinical relevance of immunohistochemically assessed RON expression in a large, single institution series of primary untreated advanced ovarian cancer patients. Methods: Immunohistochemical analysis was performed by using the polyclonal rabbit anti-RON-β antibody (C-20, clone sc-322, Santa Cruz, California). Results were expressed as the total proportion of immunostained tumor cells (RON positivity), or the percentage of cells showing strong staining of RON expression (H-RON positivity). Results: In the overall series RON positive immunoreaction was observed in 103/141 cases, while H-Ron positivity was detected in 577141 (40.4%) cases. No association between RON and H-RON expression with response to first-line treatment was documented. During the follow up period, progression and death of disease were observed in 111 (78.7%) and 76 (53.9%) cases, respectively. Cases with strong H-RON expression has a shorter overall survival (median = 35 months) than cases with low RON levels (median = 59 months) (X2 = - 2.1, p value = 0.032). In multivariate analysis, only platinum resistance, and extent of residual tumor retained an independent negative prognostic role for OS, with the percentages of H-RON positively immunostained cells showing a borderline statistical significance (p value = 0.0643). The unfavourable role of elevated percentages of H-RON expression was maintained only in the subgroup of platinum resistant recurrent ovarian cancer patients (X2 = 3.89, p value = 0.048) compared to the platinum sensitive ones (X2 = 1.98, p value = 0.16). Conclusions: The assessment of RON expression deserves further attention as a parameter helpful to identify poor prognosis ovarian cancer patients potentially candidates to investigational agents. © 2008 Elsevier Inc. All rights reserved.

Prognostic role of the recepteur d'origine nantais (RON) expression in ovarian cancer patients / Ferrandina, G.; Martinelli, E.; Petrillo, M.; Prisco, M. G.; Zucconi, A.; Santaguida, S.; Zannoni, G.; Scambia, G.; Ferlini, C.. - In: GYNECOLOGIC ONCOLOGY. - ISSN 0090-8258. - 111:2(2008), pp. 237-243. [10.1016/j.ygyno.2008.07.013]

Prognostic role of the recepteur d'origine nantais (RON) expression in ovarian cancer patients

Petrillo M.;
2008

Abstract

Objective: The aim of the study was to investigate the potential clinical relevance of immunohistochemically assessed RON expression in a large, single institution series of primary untreated advanced ovarian cancer patients. Methods: Immunohistochemical analysis was performed by using the polyclonal rabbit anti-RON-β antibody (C-20, clone sc-322, Santa Cruz, California). Results were expressed as the total proportion of immunostained tumor cells (RON positivity), or the percentage of cells showing strong staining of RON expression (H-RON positivity). Results: In the overall series RON positive immunoreaction was observed in 103/141 cases, while H-Ron positivity was detected in 577141 (40.4%) cases. No association between RON and H-RON expression with response to first-line treatment was documented. During the follow up period, progression and death of disease were observed in 111 (78.7%) and 76 (53.9%) cases, respectively. Cases with strong H-RON expression has a shorter overall survival (median = 35 months) than cases with low RON levels (median = 59 months) (X2 = - 2.1, p value = 0.032). In multivariate analysis, only platinum resistance, and extent of residual tumor retained an independent negative prognostic role for OS, with the percentages of H-RON positively immunostained cells showing a borderline statistical significance (p value = 0.0643). The unfavourable role of elevated percentages of H-RON expression was maintained only in the subgroup of platinum resistant recurrent ovarian cancer patients (X2 = 3.89, p value = 0.048) compared to the platinum sensitive ones (X2 = 1.98, p value = 0.16). Conclusions: The assessment of RON expression deserves further attention as a parameter helpful to identify poor prognosis ovarian cancer patients potentially candidates to investigational agents. © 2008 Elsevier Inc. All rights reserved.
Prognostic role of the recepteur d'origine nantais (RON) expression in ovarian cancer patients / Ferrandina, G.; Martinelli, E.; Petrillo, M.; Prisco, M. G.; Zucconi, A.; Santaguida, S.; Zannoni, G.; Scambia, G.; Ferlini, C.. - In: GYNECOLOGIC ONCOLOGY. - ISSN 0090-8258. - 111:2(2008), pp. 237-243. [10.1016/j.ygyno.2008.07.013]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11388/245545
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 18
social impact